Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a solid tumour (a type of cancer that forms a lump) that has come back or spread to other parts of the body
- People who are well enough to carry out normal daily activities with little or no limitation (measured by a standard health scale called ECOG, scores 0 or 1)
- People in a specific part of the trial (called DES) who have at least one tumour that can be measured on a scan, using standard measurement guidelines
- People who have tumour tissue available from a previous sample, or who are willing to have a small tumour biopsy taken before treatment begins, if it is safe to do so
- People with triple-negative breast cancer (TNBC), or those who have a history of cancer spreading to the brain or who have neurological symptoms, must have a brain MRI scan done during the screening period (or within 30 days before screening)
Who may not be able to join:
- People who have previously been treated with a type of targeted cancer drug (called an Antibody Drug Conjugate, or ADC) that contains a specific ingredient called an auristatin payload
- People who have had major surgery within 28 days before starting the study, or certain other cancer treatments within specified recent timeframes before starting the study (confirm with trial site for exact timeframes)
- People who have been diagnosed with another cancer that needed active treatment such as surgery, radiation, or systemic therapy within the past 2 years — though some minor skin cancers and certain early-stage cancers may be exceptions
- People who have untreated cancer that has spread to the brain, or a history of cancer spreading to the lining around the brain or spinal cord
- People who have previously received treatment that specifically targeted a protein called B7-H4
- People with a history of serious liver conditions, such as cirrhosis, liver scarring, or enlarged veins in the oesophagus or stomach caused by liver disease
- People with a severe, uncontrolled illness affecting the heart, lungs, or metabolism, or any other serious ongoing condition that could raise the risk of harmful side effects or interfere with the trial
- People with a clinically significant heart or blood vessel condition (confirm with trial site for specific details)
- People with active inflammation of the cornea (the front surface of the eye)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert Burger, MD, Day One Biopharmaceuticals, Inc.
Phone: 1-650-484-0899
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with Emi-Le during the first cycle of treatment (Dose Escalation); Incidence of adverse events (Dose Escalation and Dose Expansion); Objective Response Rate (ORR) (Dose Expansion and EMBLEM-1)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.